Efficacy and safety of caspofungin for the treatment of invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.
J Int Med Res
; 52(3): 3000605241237878, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38530040
ABSTRACT
OBJECTIVES:
We assessed the efficacy of a 3-week primary or salvage caspofungin regimen in patients with chronic obstructive pulmonary disease (COPD) and concomitant proven or suspected invasive pulmonary aspergillosis (IPA).METHODS:
Forty-four patients were treated with an initial loading caspofungin dose of 70 mg, followed by a daily dose of 50 mg for 20 days. The main efficacy endpoint was clinical effectiveness. Secondary endpoints included the clinical efficacy of caspofungin after 1 week, therapeutic efficacy based on the European Organization for Research and Treatment of Cancer and Mycoses Study Group Education and Research Consortium (EORTC/MSG) criteria, the sensitivity of different Aspergillus strains to caspofungin in vitro, and the safety of caspofungin.RESULTS:
An assessment of 42 patients in the intention-to-treat group revealed efficacy rates of 33.33% within 1 week and 38.10% within 3 weeks. According to the EORTC/MSG criteria, the treatment success rate was 38.10%. The success rate of first-line treatment was 54.76%, whereas salvage treatment had a success rate of 45.24%. No adverse events were reported among the participants.CONCLUSIONS:
Caspofungin is effective and safe as an initial or salvage treatment for patients with IPA and COPD.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Aspergilosis
/
Enfermedad Pulmonar Obstructiva Crónica
/
Aspergilosis Pulmonar Invasiva
Límite:
Humans
Idioma:
En
Revista:
J Int Med Res
Año:
2024
Tipo del documento:
Article
País de afiliación:
China